Carboplatin

Catalog No.S1215 Synonyms: JM-8, CBDCA, NSC 241240

Molecular Weight(MW): 371.25

Carboplatin is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells.

Cited by 29 Publications

Nat Med, 2019, 25(5):838-849

PubMed: 31011202 ( click the link to review the publication )

Cancer Cell, 2013, 24(5):617-30

PubMed: 24229709 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(19):5925-5936

PubMed: 31300448 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):199

PubMed: 31362778 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):199

PubMed: 31362778 ( click the link to review the publication )

Cell Death Dis, 2019, 10(10):714

PubMed: 31558709 ( click the link to review the publication )

Sci Rep, 2019, 9(1):11153

PubMed: 31371750 ( click the link to review the publication )

Biol Res, 2019, 52(1):13

PubMed: 30894224 ( click the link to review the publication )

Oncotarget, 2019, 10(49):5011-5019

PubMed: 31489111 ( click the link to review the publication )

Oncotarget, 2019, 10(62):6691-6712

PubMed: 31803363 ( click the link to review the publication )

Cancer Lett, 2018, 436:75-86

PubMed: 30120964 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2551-2563

PubMed: 30217967 ( click the link to review the publication )

Neoplasia, 2018, 20(8):826-837

PubMed: 30015158 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(6):1397-1406

PubMed: 27663600 ( click the link to review the publication )

Cell Rep, 2017, 19(1):101-113

PubMed: 28380350 ( click the link to review the publication )

Breast Cancer Res, 2017, 19(1):93

PubMed: 28810913 ( click the link to review the publication )

Oncotarget, 2017, 8(31):51733-51747

PubMed: 28881682 ( click the link to review the publication )

Sci Rep, 2017, 7:42319

PubMed: 28176879 ( click the link to review the publication )

Nat Commun, 2016, 7:12351

PubMed: 27484502 ( click the link to review the publication )

Nat Commun, 2016, 7:12088

PubMed: 27357444 ( click the link to review the publication )

Mol Cancer Ther, 2016, 10.1158/1535-7163.MCT-16-0004

PubMed: 27256375 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71696-71702

PubMed: 27765934 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2015, 112(6):1839-44

PubMed: 25605917 ( click the link to review the publication )

J Transl Med, 2015, 13:239

PubMed: 26198537 ( click the link to review the publication )
Arch Biochem Biophys, 2015, 10.1016/j.taap.2015.03.018

PubMed: 25843419 ( click the link to review the publication )

Oncotarget, 2015, 6(29):27923-37

PubMed: 26314846 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(14):3849-61

PubMed: 24850841 ( click the link to review the publication )

University of South Florida, 2014, /

PubMed: / ( click the link to review the publication )

PLoS One, 2013, 8(9):e72637

PubMed: 24039787 ( click the link to review the publication )

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description

Carboplatin is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells.

Features

A DNA synthesis inhibitor.

Targets

DNA synthesis ^[1]
(A2780, SKOV-3, IGROV-1, HX62 cells)

In vitro

Carboplatin exhibits an inhibitory effect on cell proliferation in a human ovarian cancer cell line panel, including A2780, SKOV3, and IGROV-1 cells with IC50 of 6.1 μM, 12.4 μM and 2.2 μM, respectively. ^[1] Carboplatin also show the anti-proliferative activities in lung carcinoid cell line, such as UMC-11, H727, and H835 cells with IC50 of 36.4 μM, 3.4 μM and 35.8 μM, respectively. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Tca8113/ut	NI\Oc2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYeyMVI26oDLzszN	MYC3NkBp		MnfRbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>?	NVnzS49jOjZzM{exNFU>
Tca8113/CBP	M2D0NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXXZTIp{Oi1{NfMAje69VQ>?	MmjjO\|IhcA>?		NWfJdIYycW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?=	NITReFQzPjF\|N{GwOS=>
Tca8113/PYM	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXGyMVI26oDLzszN	NYnNV5hMPzJiaB?=		M1;jUYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl?	M4PMRVI3OTN5MUC1
SKOV3	Mn3aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF3iemI3OCCvZz;tcC=>	MUexMVUh\A>?		NYDEVHlZcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgeIlu\SCmZYDlcoRmdnSueR?=	NX;QXJdwOjZzM{ewOFM>
SKOV3	MmHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3\zT\|AuPCEQvHevcYw>	MWiyOE81QC95MjDo		NI\JRYFqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfGy7	NYThWZYyOjZzMkWyO\|M>
SKOV3	NGPmUWVCeG:ydH;zbZMhSXO\|YYm=	MnniNkDPxGdxbXy=	MkC4OFghcA>?		NFH3e\|NqdmS3Y3XzJIFxd3C2b4Ppdy=>	Ml;HNlYyOjV{N{O=
OSA	MoLXR4xwdm:pZX7pZ{BCe3OjeR?=	Mn3FNk42NzVizszN			MYTy[ZN2dHS\|IHnuJIxwf2W{IHPvcI9vgSCob4LtZZRqd25iYYOgZ49ueGG{ZXSgeI8h\Wm2aHXyJGJOUTFic3nSUmEhfHKnYYTt[Y51	MXqyOlEyODZ{MB?=
A549	NVvJOVhMTnWldHnvckBCe3OjeR?=	M1\0N\|AwOjVxNUCg{txO	Mme3NlQhcA>?		MYPkc5dvemWpdXzheIV{KG2rUj2yNFUh\XiycnXzd4lwdsLi	NXL1V2RNOjV7MUezNVc>
H1975	MljiSpVkfGmxbjDBd5NigQ>?	MWiwM\|I2NzVyIN88US=>	MYSyOEBp		MUPkc5dvemWpdXzheIV{KG2rUj2yNFUh\XiycnXzd4lwdsLi	M3XDVVI2QTF5M{G3
A549	NVfQPZgyTnWldHnvckBCe3OjeR?=	M1zMeFAwOjVxNUCg{txO	NFjGVYczPCCq		NWPQc4hTfXC{ZXf1cIF1\XNibXnSMVIyQCCneIDy[ZN{cW:w	M3vQWVI2QTF5M{G3
H1975	Mo\5SpVkfGmxbjDBd5NigQ>?	MX6wM\|I2NzVyIN88US=>	MYSyOEBp		MW\1dJJm\3WuYYTld{BucVJvMkG4JIV5eHKnc4Ppc44>	NXHWdFFQOjV7MUezNVc>
A549	M4fpZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGrzO5IzPSEQvF2=	MVqyOEBp		MWfpcohq[mm2czDj[YxtKGe{b4f0bC=>	MWiyOVkyPzNzNx?=
H1975	M1LCTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmnhNlUh\|ryP	M37nRlI1KGh?		MkPObY5pcWKrdIOgZ4VtdCCpcn;3eIg>	NHfLd28zPTlzN{OxOy=>
MDA-MB-231	NGXaeZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnW0NE0zOjBizsznM41t	MXy3NkBp		NWjUemRiUUN3MNMgQUA5PiEQvF2=	MmW1NlU5Ozd4OUG=
T47D	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3jZWFAuOjJyIN88[{9udA>?	MVG3NkBp		MYDJR\|UxyqB;IES4Mlkh\|ryP	MW[yOVg{PzZ7MR?=
LCTCC	M2OxfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX\qO\|NnUUN3ME2zMljjiIoEtV2=	NWLxemZsOjV5N{OxOlc>
MCTCC	M2D2SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUTBeZM3UUN3ME2yMljjiIoEtV2=	MXOyOVc4OzF4Nx?=
MegTCC	NFTFTmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoDSTWM2OD12LkJihKnDvU1?	M3zaNVI2Pzd\|MU[3
MonoTCC	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV;Kd\|JKUUN3ME21MlbjiIoEtV2=	NV3NZoxFOjV5N{OxOlc>
MCF7	NYqxc4VvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVOyNEDPxE1?	Mn:1O\|IhcA>?		MmjtbY5lfWOnczDj[YxtKGSnYYToJI9nKEiSMd8yMYRmeGyndHXkJG1ETjdiY3XscJM>	NUfxRZpLOjV5NkmwNlU>
A-549	MoCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYrDTJhpOC53IN88US=>	NIDmVVQzPCCq	NFSzO\|NFVVORwrC=	M3nEO4lvcGmkaYTzJINmdGxiZ4Lve5RpKHOrZ37p[olk[W62bIm=	M3vNdVI2PzV3Nkmw
A-549	NHnuSFVCeG:ydH;zbZMhSXO\|YYm=	NXnORVhbOC53IN88US=>	MkXXOFghcA>?	NU\4WWJWTE2VT9Mg	MmrQd4hwf3NiZXHycJkh[XCxcITvd4l{KG[nYYT1doV{KGmwY3z1[Ilv\yCkbHXiZolv\yCjbnSgZ4hzd22jdHnuJINwdmSnboPheIlwdg>?	M1LwdlI2PzV3Nkmw
A-549	MUHGeYN1cW:wIFHzd4F6	M3nM[lAvPSEQvF2=	Mn7IOFghcA>?	MYXEUXNQyqB?	MXTzbI94eyCjYnXydoFvfCCvaXPyc5R2[nWuZTDkbZNzfXC2aX;u	MkTVNlU4PTV4OUC=
A-549	NYD3Vm1STnWldHnvckBCe3OjeR?=	NIPTZosxNjVizszN	NFnvdYU1QCCq	MlPBSG1UV8Li	MWfpcohq[mm2czDv[kBk\WyuIH3p[5JifGmxbtMg	MoXjNlU4PTV4OUC=
RMG-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml[0TWM2OD1{OD64JOKyKDNwNjDt[{9N	NWSzNZNsOjV5Mk[5NVM>
FN-RMG-1	NG[zXIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVXJR\|UxRTRyLkWgxtEhPC5{IH3nM2wLKM7:TR?=	M2rBTlI2PzJ4OUGz
RMG-1-hFUT	Mn;VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1;ET2lEPTB;NUiuNUDDuSB{LkSgcYcwVA>?	NIDSfpYzPTd{NkmxNy=>
FN-RMG-1-hFUT	NVLENotzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmHRTWM2OD1zMUiuPEDDuSBzMz64JI1oN0x?	MnnyNlU4OjZ7MUO=
CHP-134	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFnxVmkyKM7:TR?=		M2LwPGROW00EoB?=	Mn7mbY5pcWKrdIOgd4lodmmoaXPhcpQh[2WubDDndo94fGhiY3;tZolv\WRid3n0bEBIW0t{OEOwN\|cy	MXuyOVY2QDR4Mx?=
IMR-32	Ml3LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWi3U3JpOSEQvF2=		NYXl[4Z2TE2VT9Mg	NYLyUYhscW6qaXLpeJMhe2mpbnnmbYNidnRiY3XscEBoem:5dHigZ49u[mmwZXSge4l1cCCJU1uyPFMxOzdz	MYiyOVY2QDR4Mx?=
CHP-134	MVvGeYN1cW:wIFHzd4F6	MlyxNVAh\|ryPwrC=		MoLvSG1UV8Li	MmS1bY5lfWOnczDhdI9xfG:\|aYOgd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJGdUUzJ6M{CzO\|E>	M32zdVI2PjV6NE[z
IMR-32	M2jod2Z2[3Srb36gRZN{[Xl?	M17lelExKM7:TdMg		Mn7ISG1UV8Li	MYrpcoR2[2W\|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6KGOxbXLpcoVlKHerdHigS3NMOjh\|MEO3NS=>	M2P4d\|I2PjV6NE[z
A549	M4HOcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{OwZlAvOi12MECwJO69VQ>?	M2DldVczKGh?		NILVbm9KSzVyPUGyOkDDuSB3LkCg{txO	M2DoSlI2PjJ3MkSz
A549/CDDP	M4fCUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVmwMlIuPDByMDFOwG0>	MljIO\|IhcA>?		M{jYNGlEPTB;MkSwxsDDucLiNEWuO{DPxE1?	M3[5RVI2PjJ3MkSz
H460	M3LWR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NGfLc5YzPCCq	M3rIdWROW09?	NWfWdVVKUUN3ME23Mlkh\|ryP	NG\JNGUzPTV7OUm5OS=>
H460	NXraWJBtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWXneXBIPy57IN88US=>	NYLVfIcyOjRiaB?=	NXrJXHFSTE2VTx?=	MYXzbI94eyCjIILh[Ilwe2Wwc3n0bZpqdmdiZX\m[YN1KHSxIGitdoF6ew>?	M3;CSVI2PTl7OUm1
NRK-52E	NVu4PJh5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWH1Vm14PzMEoHlCpC=>		NXXKcWhYUUN3ME2xNFAhyrFiMUKuPUDPxE1?	MW[yOVU3PTZyMx?=
RGE	MoniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3f0RVczyqCqwrC=		MlrTTWM2OD1{MjFCtUA4NjRizszN	MmLFNlU2PjV4MEO=
NRK-52E	M1jhb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MUG3NuKhcMLi		MoDGTWM5OD1zN{mgxtEhQS53IN88US=>	NXLvNHFbOjV3NkW2NFM>
RGE	NF3jcW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NG\hNFM4OsLiaNMg		NXXRbIdkUUN6ME22N{DDuSB5LkSg{txO	Mn7sNlU2PjV4MEO=
SK-OV-3	NUH3UIZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MojHO\|IhcA>?		NWm2Xm5YUUN3ME2xNFQvQCEQvF2=	NWjVfJlCOjV3MkCxN\|I>
ES-2	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MkfoO\|IhcA>?		NH;6S\|JKSzVyPUG0MlYh\|ryP	M2nkXlI2PTJyMUOy
OVCAR-8	NGnUeIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NF7hPYE4OiCq		NImw[GpKSzVyPUm2MlAh\|ryP	MVyyOVUzODF\|Mh?=
3AO	NUfIblNET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmLwO\|IhcA>?		MonuTWM2OD14Mz60JO69VQ>?	Ml;sNlU2OjBzM{K=
A2780	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NIroTGM4OiCq		M1jDbGlEPTB;MUS1Mlch\|ryP	NHe2RYIzPTV{MEGzNi=>
SW626	NGDBbFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVj4R\|E6PzJiaB?=		MkjaTWM2OD17Nz6wJO69VQ>?	M4TG[lI2PTJyMUOy
OVCAR-3	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlLuO\|IhcA>?		MWjJR\|UxRTN{Lk[g{txO	Mn7vNlU2OjBzM{K=
A549	NF3TTWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2[2d2lEPTB;MUWxMlU3KMLzIEWzMlA3KM7:TR?=	MVmyOVI4PzR4MR?=
4T1	NYPRdlJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVr3TFB[UUN3ME24OE43OiEEsTCzNE4xPSEQvF2KJO69VQ>?	MX6yOVI4PzR4MR?=
BALB/3T3	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHvJTYxKSzVyPUG0MlMxKMLzIE[uOlgh\|ryP	MoXDNlUzPzd2NkG=
B16	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWXaSGx5UUN3ME22OE4{OCEEsTC2MlgyKM7:TR?=	NYXafmNZOjV{N{e0OlE>
DU 145	NHvOOXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmT2TWM2OD1\|NT6wOEDDuSBzNz61OEDPxE1?	MXGyOVI4PzR4MR?=
FaDu	M{LPWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHfoN\|hKSzVyPUS1MlM6KMLzIEGxMlUxKM7:TR?=	MVmyOVI4PzR4MR?=
HCV-29T	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmntTWM2OD12OD61O{DDuSB{Mj60PUDPxE1?	MnnMNlUzPzd2NkG=
HL-60	NUDlelNiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2G5PWlEPTB;MUGuNVAhyrFiND60O{DPxE1?	Mmq4NlUzPzd2NkG=
HT-29	M3L4UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVvJR\|UxRTh7LkG2JOKyKDF6Lki2JO69VQ>?	NF7pOFUzPTJ5N{S2NS=>
H146	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2jyc2lEPTB;NEmuOuKyOTNwMTFOwG0>	M2fLPFI2OTJ2Mkiy
H187	NHi1OndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2jJdGlEPTB;MUKuO:KyOi55IN88US=>	NVHzc\|RDOjVzMkSyPFI>
H128	NH\sOllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmH3TWM2OD1zME[uOOKyQS54IN88US=>	NHX6[nUzPTF{NEK4Ni=>
H69	M2[4bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVjJR\|UxRTd4LkpCtVI4NjhizszN	M1TN[lI2OTJ2Mkiy
H209	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGDQN2JKSzVyPUK1PE4yyrF7OT64JO69VQ>?	NYLRPFF4OjVzMkSyPFI>
DMS153	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MULJR\|UxRTV5LklCtVkvOiEQvF2=	NHrlTG8zPTF{NEK4Ni=>
H526	NYS5UJM{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4HYPWlEPTB;Nz6yxtEyNjdizszN	NE\mZYMzPTF{NEK4Ni=>
DMS114	NFHwT3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoPJTWM2OD16NT64xtEyOi56IN88US=>	M17ycFI2OTJ2Mkiy
DMS53	NHKxN4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHXYSmRKSzVyPUG0Ok4zyrF\|Nj60JO69VQ>?	NI\MeZczPTF{NEK4Ni=>
HeLa	NIe3ZmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYHjeGtYPS16MDFOwG0>			M1LJd4lvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk>	MnH6NlUyODl\|NkC=
MCF-7	M1vCT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWntS4lOPS16MDFOwG0>			MWPpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5	NVvRdoQxOjVzMEmzOlA>
MDA-MB-231	M2fueGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3XtTlUuQDBizszN			M{KydYlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk>	M3jLV\|I2OTB7M{[w
CaOV3	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGr5VlM4OiCq		M2DNc2lEPTB;OE[uNUDPxE1?	MnTYNlUxPjh6NEm=
OVCAR-3	NXvlZ49NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXq2eoJrPzJiaB?=		NEe1S2ZKSzVyPUG3PU42KM7:TR?=	M1z2fVI2ODZ6OES5
OVCAR-5	MlrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MYG3NkBp		Ml3CTWM2OD15NT63JO69VQ>?	MlnCNlUxPjh6NEm=
SKOV-3	M1PV[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVvDV5Z4PzJiaB?=		MYPJR\|UxRTVyNDFOwG0>	MYqyOVA3QDh2OR?=
OVCAR-4	MnWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHHiVFM4OiCq		NGXYT\|ZKSzVyPUK5NE43KM7:TR?=	MXOyOVA3QDh2OR?=
OVCAR-8	NXvXSZpuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NVS0[pJiPzJiaB?=		M1fKdWlEPTB;NkmwMlIh\|ryP	MoL6NlUxPjh6NEm=
MA148	NF3UNpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MYKyOEBp		MXjJR\|UxRTh\|LkdihKnDueLCiUGuOEDPxGdxbXy=	M3fOV\|I1QDNzMEmx
A549	NYPDb\|htT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MV6yOEBp		M17lXmlEPTB;N{e2MlDjiIoEsfMAjVEvQSEQvHevcYw>	MkDHNlQ5OzFyOUG=
MDA-MB-231	NE[3SIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXe0WI93OjRiaB?=		MkfmTWM2OD15NEiuNQKBkcLz4pEJNU4yKM7:Zz;tcC=>	NFX0W2YzPDh\|MUC5NS=>
NCI-ADR/RES	NFu5V\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NUPFS2tyOjRiaB?=		NVGzNo5KUUN3ME2xO\|U{NjEkgJpCtgKBkTRwNDFOwIcwdWx?	NXy4OWJGOjR6M{GwPVE>
MA148	NIX1SpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MVy0PEBp		NX60NIh1UUN3ME2yPE4y6oDLwsJihKkyNjBizsznM41t	NGfnRoIzPDh\|MUC5NS=>
A549	NV[yO45MT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M{OyR\|Q5KGh?		NV[2XIdUUUN3ME2xNVgvOOLCidMx5qCKOS5{IN88[{9udA>?	NWnpW4t4OjR6M{GwPVE>
MDA-MB-231	NGT5XYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NH7OVIo1QCCq		MnjrTWM2OD1zOEOuNQKBkcLz4pEJNU4zKCEQvHevcYw>	MXqyOFg{OTB7MR?=
NCI-ADR/RES	M1LOfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1u4bVQ5KGh?		MkK2TWM2OD1zOUOuNQKBkcLz4pEJNU46KM7:Zz;tcC=>	M3PZPFI1QDNzMEmx
MA148	NGnUd5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MoHrO\|IhcA>?		MlXkTWM2OD1zMz635qCKyrIkgJmxMlIh\|rypL33s	M{fBNVI1QDNzMEmx
A549	M1jP[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVvXeWFbPzJiaB?=		MWDJR\|UxRTZ2LkRihKnDueLCiUGuNUDPxGdxbXy=	NEfSdW4zPDh\|MUC5NS=>
MDA-MB-231	MoXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NF21TGk4OiCq		MX3JR\|UxRTl7LkZihKnDueLCiUGuNUDPxGdxbXy=	M4G2XFI1QDNzMEmx
NCI-ADR/RES	Mn3ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3jpSVczKGh?		M2DwWGlEPTB;M{euOQKBkcLz4pEJNU44KM7:Zz;tcC=>	M2HrRlI1QDNzMEmx
A549	MnuxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NIjzT\|Y4OiCq	MWDEUXNQ	MYLJR\|UxRTF3Mj60NFkh\|ryP	M4PyelI1PzJzM{Kz
NCI-H157	NGrLdWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MYe3NkBp	NVvrNnM2TE2VTx?=	M1viNmlEPTB;OEmuPVc4KM7:TR?=	NXLpXJpyOjR5MkGzNlM>
PC9	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NInNU\|A4OiCq		Mki5S2M2OD15MT62xtE6NjViwsXN	M2PrTFI1PjF6OEC5
A549	NVj4bYQxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NW[zc4NOPzJiaB?=		MUTHR\|UxRTF\|NtMxN\|EvPiEEtV5CpC=>	MX6yOFYyQDhyOR?=
PC9	M4Sw[2Fxd3C2b4Ppd{BCe3OjeR?=	M1i4UVExOCEEtV2=	MknGO\|IhcA>?		M17kOIlv\HWlZYOgZZBweHSxc3nz	M{HlSlI1PjF6OEC5
A549	M1KyPWFxd3C2b4Ppd{BCe3OjeR?=	NGPKclAyODBiwsXN	MX63NkBp		NVHvO4VIcW6mdXPld{BieG:ydH;zbZM>	Mkn3NlQ3OTh6MEm=
A549	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MWWyOEBp		NGrQRXJKSzFyPUGuOFc3KG6P	M{DaTVI1Ozl4NEO3
H1299	M2HafWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVWyOEBp		M1e0NWlEOTB;MD60OFMhdk1?	NYnhTmFyOjR\|OU[0N\|c>
HCC15	NWnPbpNnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NH3RVWYzPCCq		NX7S[VJSUUNzME2wMlM1PiCwTR?=	MmXENlQ{QTZ2M{e=
H157	M3jLRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVTafZJWOjRiaB?=		M1rFUWlEOTB;MD64NUBvVQ>?	MlHvNlQ{QTZ2M{e=
A2780	M3\1e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmPvTWM2OD1zND6w5qCKyrIkgJmxMlQh\|ryP	NFnvRoozPDJyOU[5Ny=>
A2780cisR	NYPWVXUyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1S5NGlEPTB;NEiuPgKBkcLz4pEJN{46KM7:TR?=	M4LRUFI1OjB7Nkmz
A2780ZD0473R	M2jSVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFTaVoJKSzVyPU[0MlbjiIoEsfMAjVMvOiEQvF2=	MXeyOFIxQTZ7Mx?=
SKOV-3	MmLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWftUo5CUUN3ME20N{416oDLwsJihKk{NjlizszN	NF;FTFMzPDJyOU[5Ny=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pChK-2 / Chk-2 ; PubMed: 30049957 Int J Mol Sci Validation of the kinase array data by Western blotting. A2780s and A2780cp cells were left untreated or treated with 50 μM carboplatin for 24 h, and the whole cell lysates were collected for Western blotting to measure total and phosphorylated Chk-2. β-a䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ p-p53(S15) / p-p53(S46) / p-p53(S392) / p53; PubMed: 30049957 Int J Mol Sci Validation of the kinase array data by Western blotting. A2780s and A2780cp cells were left untreated or treated with 50 μM carboplatin for 24 h, and the whole cell lysates were collected for Western blotting to measure total and phosphorylated p-p53. β-a䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ p-p38 / p38 / Cleaved PARP / PARP ; PubMed: 30049957 Int J Mol Sci A2780s and A2780cp cells were treated with increasing concentrations of carboplatin for 48 h. Phosphorylation of p38 and cleavage of Poly(ADP-ribose) polymerase (PARP) were analyzed by Western blotting. Two antibodies were used to examine the cleaved PARP䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ෆĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ�෋䐺痖暼瘿�෋ᾰƌ �෋Ð㺣痖�෋𢡄�෋䀷痗�෋౴�෋㵶痗�෋뺖᎒泌Itemｾ᎒Count﫨呂�෋猴፲�෋፲씢痗猸፲髸莤䥷堙᎒ｾ᎒�堞ﻮ᎒፲露𢡄	30049957
Immunofluorescence	γH2AX ; PubMed: 24348048 Onco Targets Ther Carboplatin induced DNA damage in SiHa cells. SiHa cells were exposed to 20, 40, and 80 μmol/L carboplatin for 12 hours, respectively. Immunofluorescence analysis was used to detect nuclear γ-H2AX foci formation with anti-H2AX antibody (red, fluorescein i䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ	24348048
Growth inhibition assay	Cell viability ; PubMed: 24348048 Onco Targets Ther SiHa and CaSki cells were treated with the indicated concentrations of carboplatin for 72 hours, and cell viability was measured by Cell Counting Kit-8 viability assay.	24348048

In vivo

In A2780 tumor xenografts, Carboplatin (60 mg/kg via i.p.) given as single agents shows a modest antitumor effect with the relative tumor volumes on day 6 of 8.4 compared to the control of 11.9, and the day 6 tumor weights relative to control (T/C) of 67%. ^[1] For the VC8 (Brca2-deficient) xenografts, Carboplatin treatment delays tumor growth and reduces tumor mass by 42% compared to the vehicle group. ^[3]

Protocol

Cell Research: ^[1]	- Collapse Cell lines: A2780, SKOV3, IGROV-1 and HX62 Concentrations: 0-200 μM Incubation Time: 72 hours Method: 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assays: Exponentially growing A2780, SKOV3, IGROV-1 and HX62 ovarian cancer cells are plated in 96 well plates. A range of drug concentrations are added and the plates are incubated for 72 hours to allow for 3–4 doubling times. Each experiment is carried out in triplicate. Sulforhodamine B (SRB) assays: Exponentially growing A2780 cells are plated in 96 well microtitre plates. For experiments studying concomitant exposure, cells are exposed to increasing concentrations of both drugs for 96 hours. For experiments studying the effect of sequence of exposure to 17-AAG or carboplatin cells are exposed to increasing concentrations of 17-AAG or carboplatin for 24 hours. A period of 24-hour exposure to the first agent is chosen so that the A2780 cells would be exposed to the first drug for at least one doubling time (18-24 hours). The cells are then washed with sterile phosphate buffered saline and the medium is replenished. Following this, the second drug (to which the cells are not exposed to in the first 24 hours) or medium is added for 96 hours. All experiments are carried out in triplicate. The results of combination studies are analyzed using the well-established principles of median effect analysis method. The effects of the combination are calculated using an in-house spreadsheet. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: The A2780 human ovarian cancer cell line is grown as a subcutaneous xenograft in female athymic NCr nude mice (nu/nu) in each flank. Formulation: Carboplatin is dissolved in 43% ethanol, 33% polypropylene glycol and 24% cremaphor diluted 1:7 with sterile water. Dosages: ≤60 mg/kg Administration: Administered via i.p. (Only for Reference)

Cell Research:

^[1]

- Collapse

Cell lines: A2780, SKOV3, IGROV-1 and HX62
Concentrations: 0-200 μM
Incubation Time: 72 hours
Method:
3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assays: Exponentially growing A2780, SKOV3, IGROV-1 and HX62 ovarian cancer cells are plated in 96 well plates. A range of drug concentrations are added and the plates are incubated for 72 hours to allow for 3–4 doubling times. Each experiment is carried out in triplicate. Sulforhodamine B (SRB) assays: Exponentially growing A2780 cells are plated in 96 well microtitre plates. For experiments studying concomitant exposure, cells are exposed to increasing concentrations of both drugs for 96 hours. For experiments studying the effect of sequence of exposure to 17-AAG or carboplatin cells are exposed to increasing concentrations of 17-AAG or carboplatin for 24 hours. A period of 24-hour exposure to the first agent is chosen so that the A2780 cells would be exposed to the first drug for at least one doubling time (18-24 hours). The cells are then washed with sterile phosphate buffered saline and the medium is replenished. Following this, the second drug (to which the cells are not exposed to in the first 24 hours) or medium is added for 96 hours. All experiments are carried out in triplicate. The results of combination studies are analyzed using the well-established principles of median effect analysis method. The effects of the combination are calculated using an in-house spreadsheet.

(Only for Reference)

Animal Research:

^[1]

- Collapse

Animal Models: The A2780 human ovarian cancer cell line is grown as a subcutaneous xenograft in female athymic NCr nude mice (nu/nu) in each flank.
Formulation: Carboplatin is dissolved in 43% ethanol, 33% polypropylene glycol and 24% cremaphor diluted 1:7 with sterile water.
Dosages: ≤60 mg/kg
Administration: Administered via i.p.
(Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	Water	14 mg/mL warmed (37.71 mM)
	DMSO	Insoluble
	Ethanol	Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Carboplatin SDF

Molecular Weight	371.25
Formula	C₆H₁₂N₂O₄Pt
CAS No.	41575-94-4
Storage	4°C powder
Storage	4°C or room temperature in solvent (should be freshly prepared each time)
Synonyms	JM-8, CBDCA, NSC 241240

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03968653	Recruiting	Drug: Debio 0123\|Drug: Carboplatin	Advanced Solid Tumors	Debiopharm International SA	July 30 2019	Phase 1
NCT03723967	Recruiting	Drug: Durvalumab with Carboplatin/Paclitaxel	Squamous Cell Carcinoma of the Head and Neck	Centre Leon Berard	May 16 2019	Phase 2
NCT03694834	Suspended	Drug: Pembrolizumab\|Procedure: Hysterectomy	Endometrial Cancer\|Uterine Cancer	UNC Lineberger Comprehensive Cancer Center\|Merck Sharp & Dohme Corp.	March 29 2019	Early Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Can you advise what solvent to use and the concentration for S1215 for in vitro use?
Answer:
DMSO will affact the activity of platinum agents. For in vitro use, according to our experience in dissolving this compound, we didn't find any solvent can dissolve it alone, but S1215 can be dissolved in co-solvent ethanol:water=1:2 at 15 mg/ml. We didn't test the stablility of the drug in such vehicle, so it is recommended to prepare the solution just before use.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

SCR7 ^New

SCR7 is a specific DNA Ligase IV inhibitor, which blocks nonhomologous end-joining (NHEJ). It increases the efficiency of HDR-mediated genome editing up to 19-fold using CRISPR/Cas9 in mammalian cells and mouse embryos.
Blasticidin S HCl ^New

Blasticidin S HCl is a nucleoside antibiotic isolated from Stretomyces girseochromogenes, and acts as a DNA and protein synthesis inhibitor, used to select transfected cells carrying bsr or BSD resistance genes.
YK-4-279 ^New

YK-4-279 is a potent inhibitor of EWS-FLI1 binding to RNA helicase A (RHA).
Cisplatin

Cisplatin is an inorganic platinum complex, which is able to inhibit DNA synthesis by conforming DNA adducts in tumor cells. DMF is recommended, compared with DMSO.

Features:One of the most widely used and most potent chemotherapeutic agents.
Gemcitabine HCl

Gemcitabine HCl is a DNA synthesis inhibitor with IC50 of 50 nM, 40 nM, 18 nM and 12 nM in PANC1, MIAPaCa2, BxPC3 and Capan2 cells, respectively.

Features:Gemcitabine has been used to treat pancreatic cancer and has demonstrated effective anti-tumor activity.
Oxaliplatin

Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells. DMF is recommended for dissolution.
Bleomycin Sulfate

Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.
Gemcitabine

Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.
Fluorouracil (5-Fluoracil, 5-FU)

Fluorouracil (5-Fluoracil, 5-FU) is a DNA/RNA synthesis inhibitor, which interrupts nucleotide synthetic by inhibiting thymidylate synthase (TS) in tumor cells.
Cytarabine

Cytarabine is an antimetabolic agent and DNA synthesis inhibitor with IC50 of 16 nM in wild-type CCRF-CEM cells.

Features:The 1st of a series of cancer drugs that alters the sugar component of nucleosides.

Choose Your Country or Region

By Signaling Pathways

By product type

Carboplatin

Cited by 29 Publications

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Carboplatin SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Choose Your Country or Region

By Signaling Pathways

By product type

Carboplatin

Cited by 29 Publications

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Carboplatin SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)